Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:CPINASDAQ:DUKXNASDAQ:MAPPNYSEARCA:MCRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPIIQ Real Return ETF$25.600.0%$25.60$24.07▼$25.80$7.68M0.271,842 shs500 shsDUKXOcean Park International ETF$23.95+0.1%$23.00$20.98▼$26.64$2.63MN/A1,187 shs481 shsMAPPMAP Pharmaceuticals$24.58+0.5%$0.00$0.00▼$0.00N/AN/AN/AN/AMCROIQ Hedge Macro Tracker ETF$25.80+0.0%$25.80$24.39▼$27.81$2.58MN/A515 shs100 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPIIQ Real Return ETF0.00%0.00%0.00%0.00%0.00%DUKXOcean Park International ETF+0.38%+2.26%+4.00%+1.96%+2,392,999,900.00%MAPPMAP Pharmaceuticals0.00%+2.37%+2.97%+6.27%+10.06%MCROIQ Hedge Macro Tracker ETF0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPIIQ Real Return ETFN/AN/AN/AN/AN/AN/AN/AN/ADUKXOcean Park International ETFN/AN/AN/AN/AN/AN/AN/AN/AMAPPMAP PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMCROIQ Hedge Macro Tracker ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPIIQ Real Return ETF 0.00N/AN/AN/ADUKXOcean Park International ETF 0.00N/AN/AN/AMAPPMAP Pharmaceuticals 0.00N/AN/AN/AMCROIQ Hedge Macro Tracker ETF 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPIIQ Real Return ETFN/AN/AN/AN/AN/AN/ADUKXOcean Park International ETFN/AN/AN/AN/AN/AN/AMAPPMAP PharmaceuticalsN/AN/AN/AN/AN/AN/AMCROIQ Hedge Macro Tracker ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPIIQ Real Return ETFN/AN/A18.48∞N/AN/AN/AN/AN/ADUKXOcean Park International ETFN/AN/A14.84∞N/AN/AN/AN/AN/AMAPPMAP PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/AMCROIQ Hedge Macro Tracker ETFN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPIIQ Real Return ETF$0.833.24%N/AN/AN/ADUKXOcean Park International ETF$0.502.09%N/AN/AN/AMAPPMAP PharmaceuticalsN/A2.40%N/AN/AN/AMCROIQ Hedge Macro Tracker ETF$0.622.40%N/AN/AN/ALatest MCRO, DUKX, CPI, and MAPP DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/26/2025DUKXOcean Park International ETFQuarterly$0.20393.42%6/27/20256/27/20257/2/2025(Data available from 1/1/2013 forward)Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPIIQ Real Return ETFN/ADUKXOcean Park International ETFN/AMAPPMAP PharmaceuticalsN/AMCROIQ Hedge Macro Tracker ETFN/AInsider OwnershipCompanyInsider OwnershipCPIIQ Real Return ETFN/ADUKXOcean Park International ETFN/AMAPPMAP PharmaceuticalsN/AMCROIQ Hedge Macro Tracker ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPIIQ Real Return ETFN/A300,000N/ANot OptionableDUKXOcean Park International ETFN/A110,000N/AN/AMAPPMAP PharmaceuticalsN/AN/AN/ANot OptionableMCROIQ Hedge Macro Tracker ETF147,000100,000N/ANot OptionableCPI, DUKX, MCRO, and MAPP HeadlinesRecent News About These CompaniesNo headlines for this company have been tracked by MarketBeat.comMedia Sentiment Over TimeCPI, DUKX, MCRO, and MAPP Company DescriptionsIQ Real Return ETF NYSEARCA:CPI$25.60 -0.01 (-0.04%) As of 12/12/2023CPI Inflation Hedged ETF seeks investment results, which correspond to the price and yield performance of the IQ CPI Inflation Hedged Index. The Index seeks to provide a hedge against the United States inflation rate by providing a real return or a return above the rate of inflation, as represented by the Consumer Price Index, which is published by the Bureau of Labor Statistics and is a measure of the average change in prices over time of goods and services purchased by households.Ocean Park International ETF NASDAQ:DUKX$23.95 +0.02 (+0.08%) As of 03:18 PM EasternThe Ocean Park International ETF (DUKX) is an exchange-traded fund that mostly invests in total market equity. The fund is an actively managed fund-of-funds that tactically allocates across international equity ETFs. The fund seeks to provide total return while mitigating downside risk DUKX was launched on Jul 10, 2024 and is issued by Ocean Park.MAP Pharmaceuticals NASDAQ:MAPPMAP Pharmaceuticals, Inc., incorporated on July 3, 2003, is a development-stage company. As of December 31, 2011, the Company was focusing to advance its product candidate, LEVADEX (MAP0004) orally inhaled migraine therapy, which is an orally inhaled version of dihydroergotamine mesylate (DHE), for the acute treatment of migraine. The Company had completed clinical development for LEVADEX in 2011 and submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA). LEVADEX is at-home therapy in development that patients self-administer using its hand-held TEMPO inhaler. Effective March 1, 2013, Allergen Inc acquired the entire share capital of MAP Pharmaceuticals Inc.IQ Hedge Macro Tracker ETF NYSEARCA:MCRO$25.80 +0.01 (+0.04%) As of 01/31/2023IQ Hedge Macro Tracker ETF (the Fund) is an exchange-traded fund that seeks to track, before fees and expenses, the performance of the IQ Hedge Macro Index (the Index). The Index seeks to replicate the risk-adjusted return characteristics of hedge funds that employ various hedge fund investment styles, which may include but are not limited to long/short equity, macro, market neutral, event-driven, fixed-income arbitrage, emerging markets and other strategies commonly used by hedge fund managers (the Strategy). The Fund is a fund of funds as each invests, under normal circumstances, at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in the investments included in its Index, which includes underlying funds. The Fund's investment advisor is IndexIQ Advisors LLC and its sub-advisor is Mellon Capital Management Corporation. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
